Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Receptiveness To Positive Emotion Increased By Naps With Rapid Eye Movement Sleep
Naps with rapid eye movement (REM) sleep refresh the brain"s empathetic sensitivity for evaluating human emotions by decreasing a negative bias and amplifying recognition of positive emotions, according to a research abstract that will be presented on Wednesday, June 10, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
generic viagra online
Common Antibiotics May Be Best First Treatment For Children With MRSA-related Infections
Penicillin and other antibiotics in the beta-lactam family work as well as other antibiotics to treat MRSA (methicillin-resistant Staphylococcuss aureus) infections in the skin and soft-tissue of children and may help prevent further resistance to antibiotic treatment, according to a new study funded by the Agency for Healthcare Research and Quality.
News of the day
The Characteristics Of Clarithromycin-Resistant Helicobacter pylori
Clarithromycin is currently one of the antibiotics used for eradication of Helicobacter pylori. However, reports of H. pylori resistance to this antibiotic are increasing worldwide. Clarithromycin resistance has been attributed to the presence of mutations in the 23S rRNA gene, a component of the ribosome that is the protein manufacturing machinery of all living cells. There is little information on the prevalence and characteristics of clarithromycin resistance in H. pylori strains isolated from Malaysian patients.
Endocrinology

FDA Approves Effient To Reduce The Risk Of Heart Attack In Angioplasty Patients

The U.S. Food and Drug Administration has approved the blood-thinning drug Effient tablets (prasugrel) to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery. During an angioplasty, a balloon is used to open the artery that has been narrowed by atherosclerotic plaque.Often, a tiny wire mesh scaffold (stent) is inserted into the blood vessel to help keep the artery open after the procedure. Platelets in the blood can clump around the procedure site, causing clots that can lead to heart attack, stroke, and death. Effient was studied in a 13,608-patient trial comparing it to the blood-thinning drug, Plavix (clopidogrel), in patients with a threatened heart attack or an actual heart attack who were about to undergo angioplasty. The fraction of patients who had subsequent non-fatal heart attacks was reduced from 9.1 percent in patients who received Plavix to 7.0 percent in patients who received Effient.While the numbers of deaths and strokes were similar with both drugs, patients with a history of stroke were more likely to have another stroke while taking Effient. In addition, there was a greater risk of significant, sometimes fatal bleeding seen in patients who took Effient. "Effient offers physicians an alternative treatment for preventing dangerous blood clots from forming and causing a heart attack or stroke during or after an angioplasty procedure," said John Jenkins, M.D., director of the Office of New Drugs, in the FDA"s Center for Drug Evaluation and Research."Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug." The drug"s labeling will include a boxed warning alerting physicians that the drug can cause significant, sometimes fatal, bleeding. The drug should not be used in patients with active pathological bleeding, a history of mini-strokes (transient ischemic attacks) or stroke, or urgent need for surgery, including coronary artery bypass graft surgery. Effient is manufactured by Eli Lilly and Company of Indianapolis, in partnership with Tokyo-based Daiichi Sankyo Ltd. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009